Docetaxel emulsion - Savara Pharmaceuticals

Drug Profile

Docetaxel emulsion - Savara Pharmaceuticals

Alternative Names: ANX-514; BTH-014; Polysorbate 80-free formulation of docetaxel - Savara Pharmaceuticals; SDP-014

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator ADVENTRX Pharmaceuticals
  • Developer Mast Therapeutics
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 27 Apr 2017 Mast Therapeutics merged with Savara Pharmaceuticals and will operate under the name Savara Pharmaceuticals
  • 19 Jul 2013 Biomarkers information updated
  • 11 Mar 2013 ADVENTRX is now called Mast Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top